Navigation Links
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Date:2/26/2008

-free survival, confirmed response rate, duration of response, disease control rate and safety.

The Phase 3 NSCLC monotherapy trial will be conducted concurrently with the pivotal Phase 3 first-line combination with chemotherapy NSCLC trial. Both studies will be conducted at many of the same sites and in partnership with the same global contract research organization (CRO). The first-line Phase 3 trial is also supported by a positive double-blind, placebo-controlled Phase 2 trial. For the first-line indication, Agennix has been granted a Special Protocol Assessment and Fast Track designation from the FDA, and has received favorable Scientific Advice from the EMEA. Both Phase 3 studies are expected to be active and recruiting in mid-2008.

FDA Fast Track Designation and EMEA Favorable Scientific Advice

Agennix received Fast Track designation from the FDA for the clinical development of talactoferrin as a single-agent in patients with locally advanced or metastatic NSCLC who have failed at least two prior systemic anti- cancer therapies. The Company had previously received Fast Track designation for first-line treatment of NSCLC in combination with chemotherapy.

Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and address unmet medical needs. The NSCLC monotherapy Fast Track designation was granted based on positive, randomized, placebo-controlled Phase 2 results with oral talactoferrin, and the planned Phase 3 pivotal trial.

"We are very pleased that the FDA recognizes that our lead product, talactoferrin alfa, also has potential as a single-agent treatment for patients with NSCLC who have failed previous therapies and who currently have very few options," said Dr. Rajesh Malik, Chief Medical Officer of Agennix.

Agennix also received Scientific Advice from the EMEA indicating that the planned single pivotal Phase 3 global trial with talactof
'/>"/>

SOURCE Agennix
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
7. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
8. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... MILPITAS, Calif. , July 10, 2014 ... a leader in advanced memory and analog IC solutions, ... call on Thursday, July 24, 2014, at 7:00 a.m. ... Company,s financial results for the fiscal 2014 third quarter ... conference call via telephone, dial 1-888-556-4997 before 6:50 a.m. ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
(Date:1/15/2014)... 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced sales ... compared to sales of $2,202,000 for the prior year period, ... has also shown growth over the preceding quarter,s sales, continuing ... fiscal year. Markets that experienced sales increases over the prior ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Volcano Corporation (Nasdaq: VOLC ) announced today the completion of the first ... performed in seven centers within the United States . Commercial launch of Eagle ... , , ... , , ...
... , SAN DIEGO , May 20 ... announced today that the U.S. Patent and Trademark Office has ... microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation ... to isolate cells from a bodily fluid using a flow ...
Cached Medicine Technology:Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 2Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 3Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 4Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology 2
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... July 12, 2014 Utah Valley Entrepreneurial ... startups, with awards being bestowed to companies in revenue, ... outstanding entrepreneur community with recognition for new ideas as ... with incoming revenue. , 25 Under 5 highlights outstanding ... that are under 5 years old. Award recipients were ...
(Date:7/12/2014)... Texas (PRWEB) July 12, 2014 ... Breastfeeding Made Simple as a valuable new resource for ... roughly two-thirds of American women work away from their ... sources touting the benefits of breastfeeding, but often feel ... to nurse their babies. With its evidence-based insights, and ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 ... power score of 4.1 out of 5. This ... that have been underpinning buyer negotiation power over ... procurement analyst Anna Son, “during the period, surging ... rising costs associated with new product development, have ...
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, ... looking for an affordable gown can visit Discount-Dress.com ... get their dream items. Recently, the company has announced its ... Along with that, it is also providing great discounts for ... the deadline of this promotion is July 29, 2014. ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2
... YORK (June 15, 2011) -- Ever since the Institute of ... 1999, significant attention has been paid to improving patient safety ... events, including major injury and even death, occur in private ... study -- the first of its kind -- researchers at ...
... , TUESDAY, June 14 (HealthDay News) -- Patients ... if they have elevated levels of a certain hormone, a ... (FGF-23) regulates phosphorus metabolism. It was known that levels of ... of the hormone are associated with increased risk of death ...
... where open space is plentiful and there is often ... rural elders are far more likely to be overweight ... suburban counterparts, according to a new policy brief from ... All three conditions are risk factors for heart ...
... growth is blocked by drugs targeting that path, the malignancy ... around the roadblock. In a study at UCLA,s Jonsson ... of prostate cancer was treated with conventional hormone ablation therapy ... growth of the tumor the cancer was able to ...
... Day this Sunday is a chance to recognize dads for putting ... up on the way to adulthood. But a new study ... dad,s job as a role model actually is. The study, ... and Environmentally Controlled Sibling Study," is due to be published in ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, June ... they might also sleep better, according to researchers who say ... sleeptime, may help treat insomnia. Previous research has shown ... have a higher brain metabolism in the frontal lobes, which ...
Cached Medicine News:Health News:JAMA study points to patient safety risks outside hospital walls 2Health News:JAMA study points to patient safety risks outside hospital walls 3Health News:Hormone Linked to Death Risk in Those With Early Kidney Disease 2Health News:Out of reach? Rural elders have highest rates of obesity, diabetes, heart disease 2Health News:Prostate cancer gets around hormone therapy by activating a survival cell signaling pathway 2Health News:Prostate cancer gets around hormone therapy by activating a survival cell signaling pathway 3Health News:Note to dads: Good parenting makes a difference 2Health News:Sleeptime Head-Cooling Cap Eases Insomnia, Study Finds 2Health News:Sleeptime Head-Cooling Cap Eases Insomnia, Study Finds 3
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
... design of the osteotomy staples is quite similar to ... are the inner position of the anti recoil contours ... staples). There are 3 kinds of staples: ... and the staples can have 3 different widths: 20mm, ...
A new generation of ORTHOMED S.A. fixation staples, manufactured from cobalt-chromium alloy: tried and test strength and tolerance...
... Sterile Barium Sulfate USP is specifically ... consistent imaging capabilities for todays medical ... minimally invasive surgery. Comprised of a ... even diffusion of sterile barium, resulting ...
Medicine Products: